Literature DB >> 18324629

Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner.

Sanaa M Nabha1, Emanuel Burck dos Santos, Hamilto A Yamamoto, Abdelfettah Belizi, Zhong Dong, Hong Meng, Allen Saliganan, Aaron Sabbota, R Daniel Bonfil, Michael L Cher.   

Abstract

At the cellular level, the process of bone metastasis involves many steps. Circulating cancer cells enter the marrow, proliferate, induce neovascularization, and ultimately expand into a clinically detectable, often symptomatic, metastatic deposit. Although the initial establishment and later expansion of the metastatic deposit in bone require tumor cells to possess invasive capability, the exact proteases responsible for this phenotype are not well known. The objective of our study was to take an unbiased approach to determine which proteases were expressed and functional during the initial interactions between prostate cancer cells and bone marrow stromal (BMS) cells. We found that the combination of human prostate cancer PC3 and BMS cells stimulates the invasive ability of cancer cells through type I collagen. The use of inhibitors for each of the major protease families indicated that 1 or more MMPs was/were responsible for the BMS-induced invasion. Gene profiling and semiquantitative RT-PCR analysis revealed an increased expression of several MMP genes because of PC3/BMS cell interaction. However, only MMP-12 showed an increase in protein expression. Downregulation of MMP-12 expression in PC3 cells by siRNA inhibited the enhanced invasion induced by PC3/BMS cell interaction. In vivo, MMP-12 was found to be primarily expressed by prostate cancer cells growing in bone. Our data suggest that BMS cells induce MMP-12 expression in prostate cancer cells, which results in invasive cells capable of degradation of type I collagen. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324629      PMCID: PMC3842601          DOI: 10.1002/ijc.23431

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

1.  Matrix metalloproteinases generate angiostatin: effects on neovascularization.

Authors:  L A Cornelius; L C Nehring; E Harding; M Bolanowski; H G Welgus; D K Kobayashi; R A Pierce; S D Shapiro
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

2.  Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein.

Authors:  S Chandler; J Cossins; J Lury; G Wells
Journal:  Biochem Biophys Res Commun       Date:  1996-11-12       Impact factor: 3.575

3.  Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice.

Authors:  M E Stearns; M Wang
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

4.  Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.

Authors:  J A Nemeth; J F Harb; U Barroso; Z He; D J Grignon; M L Cher
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

5.  Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients.

Authors:  Hans-Stefan Hofmann; Gesine Hansen; Günther Richter; Christiane Taege; Andreas Simm; Rolf-Edgar Silber; Stefan Burdach
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

6.  Expression and functional role of CCR9 in prostate cancer cell migration and invasion.

Authors:  Shailesh Singh; Udai P Singh; Jonathan K Stiles; William E Grizzle; James W Lillard
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

7.  Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase.

Authors:  T J Gronski; R L Martin; D K Kobayashi; B C Walsh; M C Holman; M Huber; H E Van Wart; S D Shapiro
Journal:  J Biol Chem       Date:  1997-05-02       Impact factor: 5.157

8.  Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.

Authors:  W C Duivenvoorden; H W Hirte; G Singh
Journal:  Invasion Metastasis       Date:  1997

9.  Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium.

Authors:  A F Olumi; G D Grossfeld; S W Hayward; P R Carroll; T D Tlsty; G R Cunha
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

10.  MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.

Authors:  K Holmbeck; P Bianco; J Caterina; S Yamada; M Kromer; S A Kuznetsov; M Mankani; P G Robey; A R Poole; I Pidoux; J M Ward; H Birkedal-Hansen
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

View more
  21 in total

1.  Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment.

Authors:  Alexandre Bruni-Cardoso; Lindsay C Johnson; Robert L Vessella; Todd E Peterson; Conor C Lynch
Journal:  Mol Cancer Res       Date:  2010-03-23       Impact factor: 5.852

2.  Matrix metalloproteinase-12 expression is increased in cutaneous melanoma and associated with tumor aggressiveness.

Authors:  Zixi Zhang; Shaojun Zhu; Yang Yang; Xianjie Ma; Shuzhong Guo
Journal:  Tumour Biol       Date:  2015-06-04

Review 3.  Association between MMP-12-82A/G polymorphism and cancer risk: a meta-analysis.

Authors:  Luliang Liu; Jinhuan Sun; Guolin Li; Boyu Gu; Xiaolong Wang; Huirong Chi; Fulin Guo
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 4.  Steps in prostate cancer progression that lead to bone metastasis.

Authors:  Jung-Kang Jin; Farshid Dayyani; Gary E Gallick
Journal:  Int J Cancer       Date:  2011-03-28       Impact factor: 7.396

5.  Development of an in vitro model to study the impact of BMP-2 on metastasis to bone.

Authors:  Heenam Kwon; Hyeon Joo Kim; William L Rice; Balajikarthick Subramanian; Sang-Hyug Park; Irene Georgakoudi; David L Kaplan
Journal:  J Tissue Eng Regen Med       Date:  2010-09-23       Impact factor: 3.963

6.  Homing of cancer cells to the bone.

Authors:  Anjali Mishra; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Cancer Microenviron       Date:  2011-08-09

7.  A microfluidic coculture and multiphoton FAD analysis assay provides insight into the influence of the bone microenvironment on prostate cancer cells.

Authors:  Lauren L Bischel; Benjamin P Casavant; Pamela A Young; Kevin W Eliceiri; Hirak S Basu; David J Beebe
Journal:  Integr Biol (Camb)       Date:  2014-06       Impact factor: 2.192

8.  Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.

Authors:  Sandy R Larson; Xiaotun Zhang; Ruth Dumpit; Ilsa Coleman; Bryce Lakely; Martine Roudier; Celestia S Higano; Lawrence D True; Paul H Lange; Bruce Montgomery; Eva Corey; Peter S Nelson; Robert L Vessella; Colm Morrissey
Journal:  Prostate       Date:  2013-01-17       Impact factor: 4.104

9.  MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1.

Authors:  Scott L Kominsky; Michele Doucet; Margaret Thorpe; Kristy L Weber
Journal:  Clin Exp Metastasis       Date:  2008-08-16       Impact factor: 5.150

10.  Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases.

Authors:  Theresa A Guise
Journal:  Genes Dev       Date:  2009-09-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.